Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Read more about Expanded Access Request Program for Belantamab Mafodotin (GSK2857916) in Multiple Myeloma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers Read more about TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma Read more about Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
Surveillance AFter Extremity Tumor surgerY Read more about Surveillance AFter Extremity Tumor surgerY
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer Read more about A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment Read more about A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib Read more about Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy Read more about FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency Read more about Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 Read more about An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1